Johnson & JohnsonJNJ +3.99%85 Market Cap is $613,022 Mil as of Jun. 27, 2026. GuruFocus rates JNJ with a GF Score™ of 85/100 and a GF Value™ of $190.57 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Johnson & Johnson ranks better than 99.8% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Johnson & Johnson's share price for the quarter that ended in Mar. 2026 was $244.44. Johnson & Johnson's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 2,407 Mil. Therefore, Johnson & Johnson's market cap for the quarter that ended in Mar. 2026 was $588,266 Mil.
Johnson & Johnson's quarterly market cap
increased
from Sep. 2025 ($446,157 Mil) to Dec. 2025 ($498,323 Mil) and
increased
from Dec. 2025 ($498,323 Mil) to Mar. 2026 ($588,266 Mil).
Johnson & Johnson's annual market cap
declined
from Dec. 2023 ($377,285 Mil) to Dec. 2024 ($348,089 Mil) but then
increased
from Dec. 2024 ($348,089 Mil) to Dec. 2025 ($498,323 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Johnson & Johnson's Enterprise Value for Today is $645,958 Mil.
Johnson & Johnson (NYSE:JNJ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Johnson & Johnson Market Cap Related Terms
Johnson & Johnson Market Cap Historical Data
* Premium members only.
The historical data trend for Johnson & Johnson's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Johnson & Johnson's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Johnson & Johnson Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Market Cap distribution charts can be found below:
* The bar in red indicates where Johnson & Johnson's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Johnson & Johnson's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson & Johnson (JNJ) has a Market Cap of $613,022 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Johnson & Johnson and its competitors. According to the industry distribution chart, Johnson & Johnson ranks #2 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 0.2%.
Is Johnson & Johnson's Market Cap too high?
Johnson & Johnson's current Market Cap is $613,022 Mil. The Drug Manufacturers industry median Market Cap is 205.37. Johnson & Johnson's value of $613,022 Mil is 298396.4% above this industry median. Based on the distribution chart, Johnson & Johnson ranks #2 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Johnson & Johnson has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's Market Cap compare to ABBV and MRK?
According to the Drug Manufacturers industry distribution chart, Johnson & Johnson ranks #2 out of 1023 companies for Market Cap. This places Johnson & Johnson in the top 0% of its industry — outperforming the majority of peers. The industry median Market Cap is 205.37. Johnson & Johnson's value of $613,022 Mil is 298396.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 205.37, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Johnson & Johnson's current Market Cap of $613,022 Mil is 298396.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Johnson & Johnson and its competitors. For the Drug Manufacturers industry, the median Market Cap is 205.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Johnson & Johnson's current Market Cap is $613,022 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (JNJ) is currently considered Significantly Overvalued. The stock's GF Value™ is $190.57, compared to a current price of $254.66 — trading 33.6% above its estimated fair value. The current Market Cap is $613,022 Mil and 298396.4% above the Drug Manufacturers industry median of 205.37. Johnson & Johnson's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Johnson & Johnson (JNJ), the current Market Cap is $613,022 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Johnson & Johnson (JNJ) Overvalued in 2026?
Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued.
The current stock price of $254.66 is trading 33.6% above its estimated GF Value™ of $190.57.
GuruFocus considers Johnson & Johnson to be Significantly Overvalued.
Key valuation signals for JNJ:
Market Cap: $613,022 Mil
GF Value™: $190.57 vs. price of $254.66 (33.6% above fair value)
Industry Position: 298396.4% above the Drug Manufacturers median (#2 of 1023)
No single metric tells the full story. See the JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
85GF Score
Get the complete analysis for JNJ
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JNJ has been successfully added to your 
